MX2021014286A - Proteinas multiespecificas. - Google Patents

Proteinas multiespecificas.

Info

Publication number
MX2021014286A
MX2021014286A MX2021014286A MX2021014286A MX2021014286A MX 2021014286 A MX2021014286 A MX 2021014286A MX 2021014286 A MX2021014286 A MX 2021014286A MX 2021014286 A MX2021014286 A MX 2021014286A MX 2021014286 A MX2021014286 A MX 2021014286A
Authority
MX
Mexico
Prior art keywords
multispecific proteins
multispecific
proteins
cancer
treatment
Prior art date
Application number
MX2021014286A
Other languages
English (en)
Inventor
Christian Reichen
Julia Hepp
Alexander Link
Victor Levitsky
Original Assignee
Molecular Partner AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partner AG filed Critical Molecular Partner AG
Publication of MX2021014286A publication Critical patent/MX2021014286A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Abstract

Esta divulgación se refiere a proteínas recombinantes multiespecíficas útiles para el tratamiento de cáncer.
MX2021014286A 2019-06-04 2020-06-03 Proteinas multiespecificas. MX2021014286A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962857037P 2019-06-04 2019-06-04
PCT/IB2020/055247 WO2020245746A1 (en) 2019-06-04 2020-06-03 Multispecific proteins

Publications (1)

Publication Number Publication Date
MX2021014286A true MX2021014286A (es) 2022-01-06

Family

ID=71069894

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014286A MX2021014286A (es) 2019-06-04 2020-06-03 Proteinas multiespecificas.

Country Status (16)

Country Link
US (1) US20200385488A1 (es)
EP (1) EP3980443A1 (es)
JP (1) JP2022535564A (es)
KR (1) KR20220016945A (es)
CN (1) CN114206943A (es)
AR (1) AR119080A1 (es)
AU (1) AU2020289080A1 (es)
BR (1) BR112021024236A2 (es)
CA (1) CA3139051A1 (es)
CO (1) CO2021017845A2 (es)
IL (1) IL288613A (es)
MX (1) MX2021014286A (es)
SG (1) SG11202112921VA (es)
TW (1) TW202112804A (es)
UY (1) UY38739A (es)
WO (1) WO2020245746A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4073091A1 (en) 2019-12-11 2022-10-19 Molecular Partners AG Designed ankyrin repeat domains with altered surface residues
US11466062B2 (en) 2020-05-06 2022-10-11 Molecular Partners Ag Ankyrin repeat binding proteins and their uses
CN116390937A (zh) 2020-08-11 2023-07-04 治纳辅医药科技有限公司 一种包含il-12和抗cd20抗体的融合蛋白及其应用
EP3957649A1 (en) * 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
IL305677A (en) * 2021-03-09 2023-11-01 Molecular Partners Ag A new derpin based on multispecific T-cell phases
WO2022219185A1 (en) * 2021-04-16 2022-10-20 Athebio Ag N-terminal capping modules of ankyrin repeat domains
WO2023121890A1 (en) * 2021-12-23 2023-06-29 Fbd Biologics Limited Cd47/4-1bb-targeting protein complex and methods of use thereof
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024037743A1 (en) * 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
WO2023194628A2 (en) * 2022-08-16 2023-10-12 Athebio Ag Variants of ankyrin repeat domains

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
DK2358746T3 (da) 2008-11-03 2020-12-21 Molecular Partners Ag Bindingsproteiner til inhibering af vegf-a-receptorinteraktionen
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
MY162737A (en) 2010-09-09 2017-07-14 Pfizer 4-1bb binding molecules
EP3514169B1 (en) 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
MX2014015825A (es) 2012-06-28 2015-08-10 Molecular Partners Ag Proteinas de repeticion de anquirina diseñadas que se unen al factor de crecimiento derivado de plaquetas.
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
JP6486908B2 (ja) 2013-05-31 2019-03-20 モレキュラー パートナーズ アクチェンゲゼルシャフト 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
WO2016029073A2 (en) 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
IL282922B (en) 2014-11-14 2022-08-01 Hoffmann La Roche Antigen binding molecules containing a trimer of a tnf family ligand
KR102427117B1 (ko) * 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
ES2953516T3 (es) 2016-09-22 2023-11-14 Molecular Partners Ag Proteínas de unión recombinantes y su uso

Also Published As

Publication number Publication date
TW202112804A (zh) 2021-04-01
UY38739A (es) 2020-12-31
CO2021017845A2 (es) 2022-01-17
WO2020245746A1 (en) 2020-12-10
KR20220016945A (ko) 2022-02-10
IL288613A (en) 2022-02-01
JP2022535564A (ja) 2022-08-09
AU2020289080A1 (en) 2021-12-23
CN114206943A (zh) 2022-03-18
SG11202112921VA (en) 2021-12-30
US20200385488A1 (en) 2020-12-10
AR119080A1 (es) 2021-11-24
CA3139051A1 (en) 2020-12-10
BR112021024236A2 (pt) 2022-04-26
EP3980443A1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
MX2021014286A (es) Proteinas multiespecificas.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
PH12018501268A1 (en) Compounds useful as kinase inhibitors
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
PH12019501959A1 (en) Therapeutic rna
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2016004570A (es) Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2022000449A (es) Conjugados peptídicos de citotoxinas como terapéuticos.
MX2022002682A (es) Anticuerpos anti-cd73.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
PH12020551791A1 (en) Methods for the production of methacrylates
EA201890177A1 (ru) Мультиспецифические связывающие белки
WO2019023315A3 (en) RAC INHIBITORS
MX2022000450A (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.